Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (9): 765-770.doi: 10.35541/cjd.20210039

• Guidelines and Consensus • Previous Articles     Next Articles

Chinese expert consensus on cyclophosphamide for the treatment of autoimmune dermatoses

Autoimmune Disease Group, China Dermatologist Association   

  1. Autoimmune Disease Group, China Dermatologist Association
  • Received:2021-01-15 Revised:2021-06-10 Online:2021-09-15 Published:2021-09-02
  • Contact: He Yanling; Li Hengjin;

Abstract: 【Abstract】 Cyclophosphamide is a broad-spectrum antineoplastic drug, and is also used as an immunosuppressant for the treatment of a variety of autoimmune skin diseases, such as systemic lupus erythematosus, dermatomyositis, scleroderma, pemphigus and pemphigoid. This consensus summarizes the mechanism of action, indications, usage and dosage of cyclophosphamide, adverse reactions and cautions during the treatment of immune skin diseases with it, as well as its application in special populations. It is hoped that this consensus will provide a reference for physicians in dermatology and relevant specialities in rational application of cyclophosphamide in the treatment of immune-related skin diseases.

Key words: Cyclophosphamide, Therapy, Lupus erythematosus, systemic, Dermatomyositis, Scleroderma, systemic, Autoimmune skin diseases, Expert consensus